MX2020008472A - Metodos y reactivos para detectar y evaluar la genotoxicidad. - Google Patents

Metodos y reactivos para detectar y evaluar la genotoxicidad.

Info

Publication number
MX2020008472A
MX2020008472A MX2020008472A MX2020008472A MX2020008472A MX 2020008472 A MX2020008472 A MX 2020008472A MX 2020008472 A MX2020008472 A MX 2020008472A MX 2020008472 A MX2020008472 A MX 2020008472A MX 2020008472 A MX2020008472 A MX 2020008472A
Authority
MX
Mexico
Prior art keywords
subject
directed
technology
genotoxicity
assessing
Prior art date
Application number
MX2020008472A
Other languages
English (en)
Inventor
Jesse J Salk
Charles Clinton Ill VALENTINE
Original Assignee
Twinstrand Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twinstrand Biosciences Inc filed Critical Twinstrand Biosciences Inc
Publication of MX2020008472A publication Critical patent/MX2020008472A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/191—Modifications characterised by incorporating an adaptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Los métodos, sistemas y kits con reactivos para evaluar la genotoxicidad se describen en la presente descripción. La genotoxicidad y sus mecanismos de acción pueden determinarse a los pocos días de la exposición del sujeto. Algunas modalidades de la tecnología están dirigidas a utilizar la Secuenciación Dúplex para evaluar un potencial genotóxico de un compuesto (por ejemplo, un compuesto químico) en un sujeto expuesto. Otras modalidades de la tecnología están dirigidas a utilizar la Secuenciación Dúplex para determinar una firma mutacional asociada con un agente genotóxico; y/o un nivel umbral seguro de exposición a genotoxinas. Las modalidades adicionales de la tecnología están dirigidas a identificar uno o más agentes genotóxicos a los que un sujeto puede haberse expuesto mediante la comparación del espectro de mutación del ADN del sujeto con el espectro de mutación de compuestos mutagénicos conocidos. Una vez que se identifica o confirma una exposición a genotoxina en un sujeto, después se proporciona un curso terapéutico de tratamiento profiláctico y/o inhibitorio.
MX2020008472A 2018-02-13 2019-02-13 Metodos y reactivos para detectar y evaluar la genotoxicidad. MX2020008472A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630228P 2018-02-13 2018-02-13
US201862737097P 2018-09-26 2018-09-26
PCT/US2019/017908 WO2019160998A1 (en) 2018-02-13 2019-02-13 Methods and reagents for detecting and assessing genotoxicity

Publications (1)

Publication Number Publication Date
MX2020008472A true MX2020008472A (es) 2020-11-11

Family

ID=67619087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008472A MX2020008472A (es) 2018-02-13 2019-02-13 Metodos y reactivos para detectar y evaluar la genotoxicidad.

Country Status (13)

Country Link
US (1) US20210355532A1 (es)
EP (1) EP3752639A4 (es)
JP (2) JP7420388B2 (es)
KR (1) KR20200123159A (es)
CN (1) CN111836905A (es)
AU (2) AU2019221549C1 (es)
BR (1) BR112020016516A2 (es)
CA (1) CA3091022A1 (es)
IL (1) IL276637A (es)
MX (1) MX2020008472A (es)
RU (1) RU2020130024A (es)
SG (1) SG11202007648WA (es)
WO (1) WO2019160998A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844428B2 (en) 2015-04-28 2020-11-24 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
PL3387152T3 (pl) 2015-12-08 2022-05-09 Twinstrand Biosciences, Inc. Ulepszone adaptory, sposoby i kompozycje do sekwencjonowania dupleksowego
US10844429B2 (en) 2017-01-18 2020-11-24 Illumina, Inc. Methods and systems for generation and error-correction of unique molecular index sets with heterogeneous molecular lengths
US11028435B2 (en) 2017-05-01 2021-06-08 Illumina, Inc. Optimal index sequences for multiplex massively parallel sequencing
CN110832087B (zh) 2017-05-08 2025-03-18 伊鲁米那股份有限公司 用于多核苷酸样品的索引的通用短衔接子
US11447818B2 (en) 2017-09-15 2022-09-20 Illumina, Inc. Universal short adapters with variable length non-random unique molecular identifiers
ES2977793T3 (es) 2017-11-08 2024-08-30 Twinstrand Biosciences Inc Reactivos y adaptadores para la secuenciación de ácidos nucleicos y métodos para fabricar dichos reactivos y adaptadores
WO2020014693A1 (en) 2018-07-12 2020-01-16 Twinstrand Biosciences, Inc. Methods and reagents for characterizing genomic editing, clonal expansion, and associated applications
GB201911095D0 (en) * 2019-08-02 2019-09-18 Randox Laboratories Ltd Biological status classification
US20240006080A1 (en) * 2020-12-07 2024-01-04 Hoffmann-La Roche Inc. Techniques for generating predictive outcomes relating to oncological lines of therapy using artificial intelligence
CN112614544B (zh) * 2020-12-28 2024-05-17 杭州瑞普基因科技有限公司 Kraken2软件输出结果的优化方法及鉴定样本中物种类型的方法
CN112553356A (zh) * 2020-12-31 2021-03-26 江苏意诺飞生物科技有限公司 一种高通量检测和判定幽门螺旋杆菌耐药性的方法
CN113554285B (zh) * 2021-07-05 2024-04-26 中国水产科学研究院黄海水产研究所 暴发水母种群波动对渔业资源风险影响的量化评估方法
NL2029132B1 (en) * 2021-09-06 2023-03-21 Prinses Maxima Centrum Voor Kinderoncologie B V Means and methods for assessing genotoxicity
CN115713968A (zh) * 2022-11-21 2023-02-24 苏州新格元生物科技有限公司 一种评估基因毒性的方法、装置、存储介质和设备
US12514461B2 (en) * 2023-08-23 2026-01-06 Wisconsin Alumni Research Foundation System and method for analyzing gene expression using diffusion weighted magnetic resonance imaging (MRI)
KR102698843B1 (ko) * 2024-01-23 2024-08-26 주식회사 이콜트리 유전독성 시험 자동화 시스템 및 방법
WO2025216210A1 (ja) * 2024-04-08 2025-10-16 株式会社ペルセウスプロテオミクス 識別用分子を用いた核酸分子の特定

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510099A (en) * 1987-05-01 1996-04-23 Stratagene Mutagenesis testing using transgenic non-human animals carrying test DNA sequences
CA2139667C (en) * 1992-07-06 2005-03-29 Spencer B. Farr Methods and diagnostic kits for determining toxicity utilizing bacterial stress promoters fused to reporter genes
GB0905410D0 (en) * 2009-03-28 2009-05-13 Gentronix Ltd Genotoxicity testing
ES2828661T3 (es) * 2012-03-20 2021-05-27 Univ Washington Through Its Center For Commercialization Métodos para reducir la tasa de error de la secuenciación de ADN masiva en paralelo mediante el uso de la secuenciación de secuencia consenso bicatenaria
CA2872141C (en) * 2012-05-31 2016-01-19 Board Of Regents, The University Of Texas System Method for accurate sequencing of dna
EP2706123A1 (en) * 2012-09-05 2014-03-12 Rijksinstituut Voor Volksgezondheid En Milieu In vitro method for determining genotoxic and non-genotoxic carcinogenicity of a compound.
CN104903467B (zh) * 2012-11-05 2020-09-08 Gmdx私人有限公司 确定体细胞突变原因的方法
JP6262922B1 (ja) * 2017-02-16 2018-01-17 花王株式会社 物質の遺伝毒性の評価方法
WO2020014693A1 (en) * 2018-07-12 2020-01-16 Twinstrand Biosciences, Inc. Methods and reagents for characterizing genomic editing, clonal expansion, and associated applications

Also Published As

Publication number Publication date
KR20200123159A (ko) 2020-10-28
SG11202007648WA (en) 2020-09-29
IL276637A (en) 2020-09-30
CA3091022A1 (en) 2019-08-22
WO2019160998A1 (en) 2019-08-22
AU2019221549B2 (en) 2025-08-07
AU2025263841A1 (en) 2025-11-27
AU2019221549A1 (en) 2020-09-24
JP2024038208A (ja) 2024-03-19
US20210355532A1 (en) 2021-11-18
BR112020016516A2 (pt) 2020-12-15
JP2021513364A (ja) 2021-05-27
EP3752639A4 (en) 2021-12-01
CN111836905A (zh) 2020-10-27
RU2020130024A (ru) 2022-03-14
JP7420388B2 (ja) 2024-01-23
AU2019221549C1 (en) 2025-11-27
EP3752639A1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
PH12017502200A1 (en) Methods of diagnosing and treating cancer
Maierthaler et al. Plasma miR‐122 and miR‐200 family are prognostic markers in colorectal cancer
Correia Dias et al. Age estimation based on DNA methylation using blood samples from deceased individuals
PH12022550578A1 (en) Method for identifying responders to smarca2/4 degraders
SG11201805531UA (en) Molecular detection/diagnosis reagent for tumor
Jo et al. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer
EA201890724A1 (ru) Способы диагностики и оценки неалкогольного стеатогепатита
EA201790716A1 (ru) Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
NZ591437A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628843A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
NO20074104L (no) Fremgangsmater og systemer for diagnose, prognose og seleksjon ved behandling av leukemi
NO20093459L (no) Fremgangsmater og systemer for selvforbedring av resonneringsverktoy
BR112016018205A2 (pt) métodos de tratamento de mal de alzheimer
WO2017214373A8 (en) Diagnostic and therapeutic methods for cancer
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
EA201892542A1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
SG11201806164VA (en) Method for determining chromosome abnormalities
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
BRPI0811930B8 (pt) métodos e kit diagnóstico ou prognóstico de lúpus em um indivíduo
WO2021094622A3 (en) Computational platform to identify therapeutic treatments for neurodevelopmental conditions
WO2015070191A3 (en) Systems and methods for detection of genomic variants
WO2017042625A3 (en) Molecular subtyping, prognosis and treatment of prostate cancer
HRP20150948T1 (hr) Biomarkeri za procjenjivanje perifernog neuropatskog odgovora na lijeäśenje sa inhibitorom proteazoma
Bhattacharyya et al. CXCL10 is overexpressed in active tuberculosis patients compared to M. tuberculosis-exposed household contacts